Producer
Asahi Kasei Medical Co., Ltd.
Subsidiary of Asahi Kasei Corporation producing Rexeed and APS series PES dialyzers. Operates the Nobeoka, Miyazaki facility — a large-scale dialyzer manufacturing campus. Asahi Kasei developed the first high-flux polysulfone membrane in the 1970s and remains a major global dialyzer OEM supplier.
2
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
2 inputs Asahi Kasei Medical Co., Ltd. supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Asahi Kasei Medical Co., Ltd. makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
PES Dialyzers (Rexeed & APS Series)
55%Apheresis Systems (LDL & Platelet Apheresis)
30%Parent Asahi Kasei Corporation (Housing + Chemicals + Healthcare)
15%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Did you know2023
Asahi Kasei Medical's Liposorber LDL apheresis system is FDA-approved and used to treat familial hypercholesterolemia (FH) — a genetic disorder causing extreme LDL cholesterol levels that statins cannot adequately control. Liposorber passes patient blood through an extracorporeal column containing dextran sulfate beads that selectively bind LDL particles, lowering LDL by 50-80% per treatment session. Patients with homozygous FH (both gene copies mutated) experience LDL levels 6-10× normal despite maximum statin therapy; without apheresis they typically die of coronary disease before age 30. Asahi Kasei is the dominant global supplier of LDL apheresis columns. A dialyzer membrane company — itself a subsidiary of a Japanese housing company — is the primary treatment option for a genetic disease that was uniformly fatal in young adults before apheresis therapy became available.
Asahi Kasei Medical Co., Ltd. ↗Origin2023
Asahi Kasei Medical is a subsidiary of Asahi Kasei Corporation — a Japanese conglomerate that simultaneously: (a) builds prefabricated houses in Japan (Hebel Haus — Japan's #2 precast concrete housing brand), (b) manufactures Flemion ion exchange membranes for industrial chlor-alkali electrolysis plants, (c) produces the polysulfone dialyzer membranes that pioneered high-flux dialysis in the 1970s, and (d) makes TUFTEC rubber for automotive seals and tubing. The same corporate entity that designs suburban Japanese homes also developed the first high-flux membrane for kidney disease treatment and continues supplying chlorine production plants with ion exchange membranes. This breadth — from residential construction to life-critical medical membranes to industrial electrolysis — reflects Japan's post-war industrial conglomerate model where diversification across seemingly unrelated industries is driven by shared material science platforms.
Asahi Kasei Corporation ↗Capacity2023
Asahi Kasei developed the first commercial high-flux polysulfone dialyzer membrane in the early 1970s — a breakthrough that transformed hemodialysis by removing not just small molecules (urea, creatinine) but also middle-molecular-weight uremic toxins (beta-2 microglobulin, 11.8 kDa) that low-flux cellulosic membranes could not clear. This innovation shifted the dialysis industry from low-flux to high-flux membranes as the new standard of care. Today, Asahi Kasei's Rexeed and APS polysulfone dialyzers remain among the leading global brands. The Nobeoka, Miyazaki campus (Kyushu, Japan) produces dialyzers at industrial scale for both branded sales and OEM supply. Asahi Kasei's membrane innovation that moved the entire dialysis field to high-flux 50 years ago is largely unrecognized in Western medical history, where polysulfone innovation is sometimes credited to Fresenius.
Asahi Kasei Medical Co., Ltd. ↗